Adcendo

Drug Discovery · Frederiksberg, Denmark · Founded 2017 · Privately Held (backing)

Developer of antibody-drug conjugates designed to create new medicines for cancer patients with significant unmet needs. Adcendo is based in Frederiksberg, Denmark and was founded in 2017. It was valued at $210 million at its later-stage round in Nov 2024, the last priced event on record. It has raised $316 million across 2 recorded rounds; the latest was a $134 million Series B in Nov 2024.

PMV mark · valuation
$209.9M
Oct 2026
Priced at
its later-stage round
Nov 2024
Total raised
$315.9M
Last round
Later Stage VC (Series B)
Nov 2024

Who backs Adcendo?

21 investors
InvestorType
BpifranceOther
RA Capital ManagementAsset manager
OrbiMedGrowth equity
InnoFounderOther
Novo HoldingsOther
Denmark's Export and Investment FundVenture capital
VenrockVenture capital
BioInnovation InstituteOther
Logos CapitalHedge fund
Gilde HealthcarePE / buyout
+ 11 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Adcendo investors

21 investors are on record for Adcendo, including Bpifrance, RA Capital Management, OrbiMed and InnoFounder. The Series B in Nov 2024 drew 11 investors.

Free account
More of Adcendo with a free account
  • ·The complete investor list: 21 names
  • ·Watch Adcendo: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 21 firms already write checks for companies like Adcendo in drug discovery. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View